{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:10:37Z","timestamp":1767849037193,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"name":"NIH","award":["HHSN272201300018I"],"award-info":[{"award-number":["HHSN272201300018I"]}]},{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012423","name":"Children's Healthcare of Atlanta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008065","name":"Georgia Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-01042-4","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T06:21:09Z","timestamp":1734934869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose"],"prefix":"10.1038","volume":"9","author":[{"given":"Christina A.","family":"Rostad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inci","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kamidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etza","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theda","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Mien","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karnail","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivien","family":"Agbakoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay M.","family":"Tomashek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes B.","family":"Goll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey E.","family":"Gelber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristal","family":"Maner-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Bosinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Ortlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Wrammert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehul","family":"Suthar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"1042_CR1","doi-asserted-by":"publisher","unstructured":"Sprecher, A. Understanding the key to outbreak control\u2014Sudan virus disease in Uganda. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMp2213975 (2022).","DOI":"10.1056\/NEJMp2213975"},{"key":"1042_CR2","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","volume":"371","author":"S Baize","year":"2014","unstructured":"Baize, S. et al. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 371, 1418\u20131425 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR3","doi-asserted-by":"publisher","first-page":"e001955","DOI":"10.1136\/bmjgh-2019-001955","volume":"5","author":"S Rugarabamu","year":"2020","unstructured":"Rugarabamu, S. et al. Forty-two years of responding to Ebola virus outbreaks in sub-Saharan Africa: a review. BMJ Glob. Health 5, e001955 (2020).","journal-title":"BMJ Glob. Health"},{"key":"1042_CR4","unstructured":"Centers for Disease Control and Prevention. 2014-2016 Ebola Outbreak in West Africa, http:\/\/www.cdc.gov\/vhf\/ebola\/history\/2014-2016-outbreak\/index.html."},{"key":"1042_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.971","volume":"6","author":"M Sohan","year":"2023","unstructured":"Sohan, M., Shahriar, M., Bhuiyan, M. A. & Islam, M. R. Recent outbreak of Marburg virus disease: could it be a threat for global public health? Health Sci. Rep. 6, e971 (2023).","journal-title":"Health Sci. Rep."},{"key":"1042_CR6","unstructured":"Centers for Disease Control and Prevention. Marburg Outbreak in Rwanda Situation Summary, https:\/\/www.cdc.gov\/marburg\/situation-summary\/index.html (2024)."},{"key":"1042_CR7","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786\u2013790 (2005).","journal-title":"Nat. Med."},{"key":"1042_CR8","doi-asserted-by":"publisher","unstructured":"Singh, K. et al. A bivalent, spherical virus-like particle vaccine enhances breadth of immune responses against pathogenic Ebola viruses in rhesus macaques. J. Virol. 94. https:\/\/doi.org\/10.1128\/JVI.01884-19 (2020).","DOI":"10.1128\/JVI.01884-19"},{"key":"1042_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/infdis\/jiz364","volume":"221","author":"BM Gunn","year":"2019","unstructured":"Gunn, B. M. et al. Survivors of Ebola virus disease develop polyfunctional antibody responses. J. Infect. Dis. 221, 156\u2013161 (2019).","journal-title":"J. Infect. Dis."},{"key":"1042_CR10","doi-asserted-by":"publisher","first-page":"E7578","DOI":"10.1073\/pnas.1806200115","volume":"115","author":"S Sakabe","year":"2018","unstructured":"Sakabe, S. et al. Analysis of CD8+ T cell response during the 2013\u20132016 Ebola epidemic in West Africa. Proc. Natl. Acad. Sci. USA 115, E7578\u2013E7586 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1042_CR11","doi-asserted-by":"publisher","first-page":"e44115","DOI":"10.1371\/journal.pone.0044115","volume":"7","author":"R Zahn","year":"2012","unstructured":"Zahn, R. et al. Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS ONE 7, e44115 (2012).","journal-title":"PLoS ONE"},{"key":"1042_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard, A. J. et al. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 21, 493\u2013506 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"1042_CR13","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jama.2016.4218","volume":"315","author":"ID Milligan","year":"2016","unstructured":"Milligan, I. D. et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA 315, 1610\u20131623 (2016).","journal-title":"JAMA"},{"key":"1042_CR14","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jama.2016.20644","volume":"317","author":"RL Winslow","year":"2017","unstructured":"Winslow, R. L. et al. Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines at 1 year. JAMA 317, 1075\u20131077 (2017).","journal-title":"JAMA"},{"key":"1042_CR15","doi-asserted-by":"publisher","first-page":"e1003865","DOI":"10.1371\/journal.pmed.1003865","volume":"19","author":"Z Anywaine","year":"2022","unstructured":"Anywaine, Z. et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: a randomised, placebo-controlled, multicentre Phase II clinical trial. PLoS Med. 19, e1003865 (2022).","journal-title":"PLoS Med."},{"key":"1042_CR16","doi-asserted-by":"publisher","first-page":"e1003813","DOI":"10.1371\/journal.pmed.1003813","volume":"18","author":"H Barry","year":"2021","unstructured":"Barry, H. et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. PLoS Med. 18, e1003813 (2021).","journal-title":"PLoS Med."},{"key":"1042_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/infdis\/jiz070","volume":"220","author":"Z Anywaine","year":"2019","unstructured":"Anywaine, Z. et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. J. Infect. Dis. 220, 46\u201356 (2019).","journal-title":"J. Infect. Dis."},{"key":"1042_CR18","unstructured":"European Medicines Association. Mvabea: EPAR- Medicine Overview. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mvabea-epar-medicine-overview_en.pdf (2020)."},{"key":"1042_CR19","unstructured":"European Medicines Association. Zabdeno (Ad26.ZEBOV-GP, recombinant). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/zabdeno-epar-medicine-overview_en.pdf (2020)."},{"key":"1042_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1089\/omi.2011.0022","volume":"15","author":"A Bernstein","year":"2011","unstructured":"Bernstein, A., Pulendran, B. & Rappuoli, R. Systems vaccinomics: the road ahead for vaccinology. OMICS 15, 529\u2013531 (2011).","journal-title":"OMICS"},{"key":"1042_CR21","doi-asserted-by":"publisher","first-page":"12300","DOI":"10.1073\/pnas.1400476111","volume":"111","author":"B Pulendran","year":"2014","unstructured":"Pulendran, B. Systems vaccinology: probing humanity\u2019s diverse immune systems with vaccines. Proc. Natl. Acad. Sci. USA 111, 12300\u201312306 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1042_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/infdis\/jiz071","volume":"220","author":"G Mutua","year":"2019","unstructured":"Mutua, G. et al. Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya. J. Infect. Dis. 220, 57\u201367 (2019).","journal-title":"J. Infect. Dis."},{"key":"1042_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112650","volume":"147","author":"TT Nguyen","year":"2022","unstructured":"Nguyen, T. T. et al. Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine. Biomed. Pharmacother. 147, 112650 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"1042_CR24","doi-asserted-by":"publisher","unstructured":"Orlova, O. V., Glazkova, D. V., Bogoslovskaya, E. V., Shipulin, G. A. & Yudin, S. M. Development of modified vaccinia virus Ankara-based vaccines: advantages and applications. Vaccines 10. https:\/\/doi.org\/10.3390\/vaccines10091516 (2022).","DOI":"10.3390\/vaccines10091516"},{"key":"1042_CR25","doi-asserted-by":"publisher","unstructured":"Collier, A.-R. Y. et al. Decline of Mpox Antibody responses after modified vaccinia Ankara\u2013Bavarian Nordic vaccination. JAMA. https:\/\/doi.org\/10.1001\/jama.2024.20951 (2024).","DOI":"10.1001\/jama.2024.20951"},{"key":"1042_CR26","doi-asserted-by":"publisher","first-page":"158ra146","DOI":"10.1126\/scitranslmed.3004582","volume":"4","author":"G Wong","year":"2012","unstructured":"Wong, G. et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med. 4, 158ra146 (2012).","journal-title":"Sci. Transl. Med."},{"key":"1042_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrmicro2129","volume":"7","author":"NJ Sullivan","year":"2009","unstructured":"Sullivan, N. J., Martin, J. E., Graham, B. S. & Nabel, G. J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol 7, 393\u2013400 (2009).","journal-title":"Nat. Rev. Microbiol"},{"key":"1042_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00261-9","volume":"5","author":"R Roozendaal","year":"2020","unstructured":"Roozendaal, R. et al. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. npj Vaccines 5, 112 (2020).","journal-title":"npj Vaccines"},{"key":"1042_CR29","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1093\/infdis\/jiz657","volume":"223","author":"HR Wagstaffe","year":"2021","unstructured":"Wagstaffe, H. R. et al. Antibody-dependent natural killer cell activation after Ebola vaccination. J. Infect. Dis. 223, 1171\u20131182 (2021).","journal-title":"J. Infect. Dis."},{"key":"1042_CR30","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1172\/JCI132438","volume":"130","author":"HR Wagstaffe","year":"2020","unstructured":"Wagstaffe, H. R. et al. Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses. J. Clin. Investig. 130, 3936\u20133946 (2020).","journal-title":"J. Clin. Investig."},{"key":"1042_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jim.2018.06.002","volume":"460","author":"K Singh","year":"2018","unstructured":"Singh, K., Marasini, B., Chen, X. & Spearman, P. A novel Ebola virus antibody-dependent cell-mediated cytotoxicity (Ebola ADCC) assay. J. Immunol. Methods 460, 10\u201316 (2018).","journal-title":"J. Immunol. Methods"},{"key":"1042_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112900","volume":"488","author":"X Chen","year":"2021","unstructured":"Chen, X. et al. Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay. J. Immunol. Methods 488, 112900 (2021).","journal-title":"J. Immunol. Methods"},{"key":"1042_CR33","doi-asserted-by":"publisher","unstructured":"Rostad, C. A. et al. Functional antibody responses to SARS-CoV-2 variants in children with COVID-19, MIS-C, and after two doses of BNT162b2 vaccination. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiac215 (2022).","DOI":"10.1093\/infdis\/jiac215"},{"key":"1042_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2021.03.009","volume":"559","author":"X Chen","year":"2021","unstructured":"Chen, X. et al. The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein. Virology 559, 1\u20139 (2021).","journal-title":"Virology"},{"key":"1042_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.virol.2022.02.004","volume":"569","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. Functional antibody-dependent cell mediated cytotoxicity (ADCC) responses to vaccine and circulating influenza strains following vaccination. Virology 569, 44\u201355 (2022).","journal-title":"Virology"},{"key":"1042_CR36","doi-asserted-by":"publisher","first-page":"18754","DOI":"10.1073\/pnas.2008236117","volume":"117","author":"M Asokan","year":"2020","unstructured":"Asokan, M. et al. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proc. Natl. Acad. Sci. USA 117, 18754\u201318763 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1042_CR37","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","volume":"366","author":"BF Haynes","year":"2012","unstructured":"Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275\u20131286 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR38","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.3389\/fimmu.2019.02968","volume":"10","author":"B Su","year":"2019","unstructured":"Su, B. et al. Update on Fc-mediated antibody functions against HIV-1 beyond neutralization. Front. Immunol. 10, 2968 (2019).","journal-title":"Front. Immunol."},{"key":"1042_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/22221751.2019.1708215","volume":"9","author":"Z Zheng","year":"2020","unstructured":"Zheng, Z. et al. Contribution of Fc-dependent cell-mediated activity of a vestigial esterase-targeting antibody against H5N6 virus infection. Emerg. Microbes Infect. 9, 95\u2013110 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"1042_CR40","doi-asserted-by":"publisher","unstructured":"Gao, R., Sheng, Z., Sreenivasan, C. C., Wang, D. & Li, F. Influenza A virus antibodies with antibody-dependent cellular cytotoxicity function. Viruses 12. https:\/\/doi.org\/10.3390\/v12030276 (2020).","DOI":"10.3390\/v12030276"},{"key":"1042_CR41","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/jama.2015.1995","volume":"313","author":"L Lai","year":"2015","unstructured":"Lai, L. et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA 313, 1249\u20131255 (2015).","journal-title":"JAMA"},{"key":"1042_CR42","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1073\/pnas.1502619112","volume":"112","author":"AK McElroy","year":"2015","unstructured":"McElroy, A. K. et al. Human Ebola virus infection results in substantial immune activation. Proc. Natl. Acad. Sci. USA 112, 4719\u20134724 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1042_CR43","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nm.2447","volume":"17","author":"NJ Sullivan","year":"2011","unstructured":"Sullivan, N. J. et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 17, 1128\u20131131 (2011).","journal-title":"Nat. Med."},{"key":"1042_CR44","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/nm.3702","volume":"20","author":"DA Stanley","year":"2014","unstructured":"Stanley, D. A. et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 20, 1126\u20131129 (2014).","journal-title":"Nat. Med."},{"key":"1042_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107598","volume":"101","author":"S Singh","year":"2021","unstructured":"Singh, S., Anshita, D. & Ravichandiran, V. MCP-1: Function, regulation, and involvement in disease. Int. Immunopharmacol. 101, 107598 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"1042_CR46","first-page":"121","volume":"22","author":"M Liu","year":"2011","unstructured":"Liu, M. et al. CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 22, 121\u2013130 (2011).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1042_CR47","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3389\/fimmu.2020.01861","volume":"11","author":"LMF Merlo","year":"2020","unstructured":"Merlo, L. M. F. et al. Differential roles of IDO1 and IDO2 in T and B cell inflammatory immune responses. Front. Immunol. 11, 1861 (2020).","journal-title":"Front. Immunol."},{"key":"1042_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1060438","volume":"13","author":"M Shojaei","year":"2022","unstructured":"Shojaei, M. et al. IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study. Front. Immunol. 13, 1060438 (2022).","journal-title":"Front. Immunol."},{"key":"1042_CR49","first-page":"680","volume":"70","author":"DK Shay","year":"2021","unstructured":"Shay, D. K. et al. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine\u2014United States, March-April 2021. Mmwr 70, 680\u2013684 (2021).","journal-title":"Mmwr"},{"key":"1042_CR50","doi-asserted-by":"publisher","first-page":"e0215457","DOI":"10.1371\/journal.pone.0215457","volume":"14","author":"TL Rudge Jr.","year":"2019","unstructured":"Rudge, T. L. Jr. et al. Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples. PLoS ONE 14, e0215457 (2019).","journal-title":"PLoS ONE"},{"key":"1042_CR51","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nature06890","volume":"453","author":"J Wrammert","year":"2008","unstructured":"Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667\u2013671 (2008).","journal-title":"Nature"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01042-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01042-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01042-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T07:04:44Z","timestamp":1734937484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01042-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1042"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01042-4","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.J.A has consulted for Pfizer, Sanofi Pasteur, GSK, Janssen, Moderna, and Medscape, and his institution receives funds to conduct clinical research unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Sanofi-Pasteur, Janssen, and Micron. He also serves on a safety monitoring board for Kentucky BioProcessing, Inc. and Sanofi Pasteur. He serves on a data adjudication board for WCG and ACI Clinical. His institution has also received funding from NIH to conduct clinical trials of COVID-19 vaccines. He is now employed by Moderna and has stock\/stock options. N.R. has consulted for EMMES, Moderna, Sanofi, Seqirus, GSK, and ICON and her institution receives funds to conduct clinical research unrelated to this manuscript from Pfizer, Sanofi, Quidel, Lilly, Merck, and Vaccine Company as well as NIH to conduct translational clinical studies and interventional clinical trials. C.A.R.\u2019s institution has received funds to conduct clinical research unrelated to this manuscript from BioFire Inc, GSK, MedImmune, Micron, Janssen, Merck, Moderna, Novavax, PaxVax, Pfizer, Regeneron, Sanofi-Pasteur. Her institution has received funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines. She is co-inventor on patented RSV vaccine technology, which has been licensed to Meissa Vaccines, Inc. with royalties received. I.Y. reported research funding from the Centers for Disease Control and Prevention, National Institutes of Health, and Gates Foundation; funding to her institution to conduct clinical research from Merck, Moderna, Pfizer outside the submitted work; honorarium for advisory board from Merck and Sanofi Pasteur. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}